copy and paste this google map to your website or blog!
Press copy button and paste into your blog or website.
(Please switch to 'HTML' mode when posting into your blog. Examples: WordPress Example, Blogger Example)
Input Form:Deal with this potential dealer,buyer,seller,supplier,manufacturer,exporter,importer
(Any information to deal,buy, sell, quote for products or service)
Cancer Clinical Trials and Pipeline l Exelixis * Sairopa B V (Sairopa) and Exelixis have an exclusive clinical development and option agreement providing Exelixis the right to acquire ADU-1805 ADC = antibody-drug conjugate CRC = colorectal cancer
Building a Legacy of Oncology Excellence l Exelixis Exelixis’ unique approach to drug discovery has led to an expanded pipeline of innovative small molecules and biotherapeutics, including antibody-drug conjugates – and expanded clinical development capabilities
Our Medicines for Cancer Patients l Exelixis If you are a healthcare professional and have a question about an Exelixis product, please contact Exelixis Medical Information at medinfo@exelixis com or call 1-855-292-3935 (EXEL)
Search Careers at Exelixis Qualified and interested candidates should apply to current openings on our Exelixis Careers website or on LinkedIn, Glassdoor and Indeed Exelixis accepts no responsibility for any costs or charges incurred as a result of fraudulent activity
Exelixis Announces Detailed Results of Phase 3 CONTACT-02 Pivotal Trial . . . ALAMEDA, Calif --(BUSINESS WIRE)--Jan 25, 2024-- Exelixis, Inc (Nasdaq: EXEL) today announced detailed results from CONTACT-02, a phase 3 pivotal study evaluating cabozantinib (CABOMETYX ®) in combination with atezolizumab compared with a second novel hormonal therapy (NHT) in patients with metastatic castration-resistant prostate cancer
Leadership Team l Exelixis One of Exelixis’ greatest strengths is its culture of focused execution We’re committed to moving quickly while turning over every stone to bring new standards of care to physicians and ultimately the cancer patients we serve
Exelixis and Insilico Medicine Enter into Exclusive Global License . . . ALAMEDA, Calif NEW YORK--(BUSINESS WIRE)--Sep 12, 2023-- Exelixis, Inc (Nasdaq: EXEL) and Insilico Medicine (“Insilico”) today announced that the companies have entered into an exclusive license agreement granting Exelixis global rights to develop and commercialize ISM3091, a potentially best-in-class small molecule inhibitor of USP1
Exelixis Announces Fourth Quarter and Fiscal Year 2023 Financial . . . ALAMEDA, Calif --(BUSINESS WIRE)--Feb 6, 2024-- Exelixis, Inc (Nasdaq: EXEL) today reported financial results for the fourth quarter and fiscal year of 2023, provided an update on progress toward achieving key corporate objectives, and outlined its commercial, clinical and pipeline development milestones
Exelixis Announces Initiation of the STELLAR-305 Phase 2 3 Pivotal . . . ALAMEDA, Calif --(BUSINESS WIRE)--Dec 4, 2023-- Exelixis, Inc (Nasdaq: EXEL) today announced the initiation of STELLAR-305, a phase 2 3 pivotal trial evaluating zanzalintinib in combination with pembrolizumab versus pembrolizumab alone in patients with previously untreated PD-L1-positive recurrent or metastatic squamous cell carcinoma of the